Login / Signup

A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease.

Pui Lin ChongDavid LaightRichard J AspinallAntony HigginsonMichael H Cummings
Published in: BMC gastroenterology (2021)
ISRCTN05474560 ( https://doi.org/10.1186/ISRCTN05474560 ) Registered 9 August 2012 (retrospectively registered).
Keyphrases
  • liver injury
  • drug induced
  • double blind
  • study protocol
  • clinical trial
  • open label
  • placebo controlled
  • randomized controlled trial
  • liver fibrosis
  • lactic acid